New Zealand standardised oral formulation batch sheet

Levodopa 5 mg/mL & Carbidopa 1.25 mg/mL (Sinemet) suspension (100 mL)

Patient's name		**Storage condition**	**In a refrigerator**	**At room temperature**
NHI		Temperature	2-8°C	≤ 25°C
Date compounded		Shelf life	30 days	28 days
Batch number		Recommended storage	☑	May be stored at room temperature if this is more practical and temperatures greater than 25°C are avoided

Ingredients required and formula:

Ingredient	Supplier	Batch number	Expiry date	Standard formula	Quantity dispensed	Dispensed by	Checked by
Levodopa 100 mg & carbidopa 25 mg (Sinemet® brand)	Merk Sharp & Dohme			5 tablets			
Ora-Blend®	Perrigo			to 100 mL			
OR							
Ora-Plus®	Perrigo			50 mL			
Ora-Sweet®	Perrigo			50 mL			

Ora-Blend SF® or Ora-Sweet SF® (sugar free) can be substituted?	Yes
Calculations performed by	
Calculations checked by (pharmacist)	
Area cleared for processing by	

Instructions to compound suspension:

N**ote**: this formula is specific to the **Sinemet**® brand of levodopa 100mg and carbidopa 25mg tablets.

1. **If Ora-Blend® unavailable:** Pre-mix the Ora-Plus® and Ora-Sweet® to form the diluent.
2. Crush tablets in mortar to a fine powder.
3. Add diluent (Ora-Blend® or prepared diluent) to form a smooth paste.
4. Gradually add the diluent and transfer to the final measuring flask, rinsing mortar well. Mix well.
5. Make up to final volume and mix well.
6. Label and package product appropriately.

Labels	
Attach product label and auxiliary labels:	Label checked by

Levodopa 5 mg/mL & Carbidopa 1.25 mg/mL (Sinemet) suspension (100 mL)

Final yield	_____ mL	Checked by	
Final appearance of product			
Container	Amber plastic mission bottle.		
Compounded by	*Name:*	*Signature:*	*Date:*
Final check and product release	*Name:*	*Signature:*	*Date:*

Special instructions:

1. Shake well before use.
2. Store in a refrigerator.

References:

1. Nahata MC, Morosco RS, Leguire LE. *J Pediatr Ophthalmol Strabismus*, 2000; **37**(6): 333-337.
2. Polonini HC, Silva SL, Cunha CN, et al. *Pharmazie*, 2016; **71**(4): 185-191.

Prepared by	New Zealand Compounding Working Group		
Approved by	Medication Safety Expert Advisory Group of Health Quality and Safety Commission NZ		
Hosted by	Pharmaceutical Society of New Zealand Standard Formulations in the Practice Support section of the PSNZ website		
Version number	3.0	Version approval date	17/07/19
Document review due	01/08/21		